Jubilant Pharmova Valuation
Is JUBLPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of JUBLPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: JUBLPHARMA (₹671.8) is trading above our estimate of fair value (₹262.63)
Significantly Below Fair Value: JUBLPHARMA is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for JUBLPHARMA?
Other financial metrics that can be useful for relative valuation.
| What is JUBLPHARMA's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₹106.83b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 17.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does JUBLPHARMA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.5x | ||
WOCKPHARMA Wockhardt | 3x | n/a | ₹83.9b |
GLS Glenmark Life Sciences | 4.1x | 10.4% | ₹98.0b |
532482 Granules India | 2.2x | 11.8% | ₹100.7b |
AETHER Aether Industries | 16.6x | 36.6% | ₹111.0b |
JUBLPHARMA Jubilant Pharmova | 1.6x | n/a | ₹106.8b |
Price-To-Sales vs Peers: JUBLPHARMA is good value based on its Price-To-Sales Ratio (1.6x) compared to the peer average (6.5x).
Price to Earnings Ratio vs Industry
How does JUBLPHARMA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Sales vs Industry: JUBLPHARMA is good value based on its Price-To-Sales Ratio (1.6x) compared to the Indian Pharmaceuticals industry average (2.4x).
Price to Sales Ratio vs Fair Ratio
What is JUBLPHARMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.6x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate JUBLPHARMA's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.